These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36860910)

  • 1. Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia.
    Hanna GJ; Villa A; Mistry N; Jia Y; Quinn CT; Turner MM; Felt KD; Pfaff K; Haddad RI; Uppaluri R; Rodig SJ; Woo SB; Egloff AM; Hodi FS
    Cancer Res Commun; 2021 Oct; 1(1):30-40. PubMed ID: 36860910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of smoking status and programmed death-ligand 1 expression on the microenvironment and malignant transformation of oral leukoplakia: A retrospective cohort study.
    Yagyuu T; Funayama N; Imada M; Kirita T
    PLoS One; 2021; 16(4):e0250359. PubMed ID: 33861793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
    Chen XJ; Tan YQ; Zhang N; He MJ; Zhou G
    Pathol Res Pract; 2019 Jun; 215(6):152418. PubMed ID: 31027907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial.
    Hanna GJ; Villa A; Nandi SP; Shi R; ONeill A; Liu M; Quinn CT; Treister NS; Sroussi HY; Vacharotayangul P; Goguen LA; Annino DJ; Rettig EM; Jo VY; Wong KS; Lizotte P; Paweletz CP; Uppaluri R; Haddad RI; Cohen EEW; Alexandrov LB; William WN; Lippman SM; Woo SB
    JAMA Oncol; 2024 Jan; 10(1):32-41. PubMed ID: 37971722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of PD-1/PD-L1 on immune microenvironment in oral leukoplakia and oral squamous cell carcinoma.
    Xu SB; Wang MY; Shi XZ; Wang Q; Yu M; Zhang W; Xu XH; Liu LK
    Oral Dis; 2023 Nov; 29(8):3268-3277. PubMed ID: 35921211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of PD-1 and PD-L1 expression in oral leukoplakia and oral squamous cell carcinoma: an immunohistochemical study.
    Greeshma LR; Joseph AP; Sivakumar TT; Raghavan Pillai V; Vijayakumar G
    Sci Rep; 2023 Dec; 13(1):21698. PubMed ID: 38066025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy.
    Wu F; Jiang T; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J; Bai X; Ren S; Zhou C;
    Cancer Commun (Lond); 2022 Dec; 42(12):1331-1346. PubMed ID: 36331328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed death ligand 1 (PD-L1) expression and tumor microenvironment: Implications for patients with oral precancerous lesions.
    Yagyuu T; Hatakeyama K; Imada M; Kurihara M; Matsusue Y; Yamamoto K; Obayashi C; Kirita T
    Oral Oncol; 2017 May; 68():36-43. PubMed ID: 28438290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1/PD-L1, Treg-related proteins, and tumour-infiltrating lymphocytes are associated with the development of oral squamous cell carcinoma.
    Kujan O; Agag M; Smaga M; Vaishnaw Y; Idrees M; Shearston K; Farah CS
    Pathology; 2022 Jun; 54(4):409-416. PubMed ID: 34872754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
    Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
    Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma.
    Nowicki TS; Akiyama R; Huang RR; Shintaku IP; Wang X; Tumeh PC; Singh A; Chmielowski B; Denny C; Federman N; Ribas A
    Cancer Immunol Res; 2017 Feb; 5(2):118-126. PubMed ID: 28039162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Systematic Review of the Tumor-Infiltrating CD8
    Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():734956. PubMed ID: 34603316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a Favorable Prognostic Subgroup in Oral Squamous Cell Carcinoma: Characterization of ITGB4/PD-L1
    Ma SR; Liu JF; Jia R; Deng WW; Jia J
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
    Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
    World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.
    Yanik EL; Kaunitz GJ; Cottrell TR; Succaria F; McMiller TL; Ascierto ML; Esandrio J; Xu H; Ogurtsova A; Cornish T; Lipson EJ; Topalian SL; Engels EA; Taube JM
    JAMA Oncol; 2017 Jul; 3(7):974-978. PubMed ID: 28334399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD8+ and CD163+ infiltrating cells and PD-L1 immunoexpression in oral leukoplakia and oral carcinoma.
    Stasikowska-Kanicka O; Wągrowska-Danilewicz M; Danilewicz M
    APMIS; 2018 Sep; 126(9):732-738. PubMed ID: 30160018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of the PD-1/PD-L1 Axis for Malignant Transformation and Risk Assessment of Oral Leukoplakia.
    Ries J; Agaimy A; Wehrhan F; Baran C; Bolze S; Danzer E; Frey S; Jantsch J; Möst T; Büttner-Herold M; Wickenhauser C; Kesting M; Weber M
    Biomedicines; 2021 Feb; 9(2):. PubMed ID: 33669300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Programmed Death-Ligand 1 in Laryngeal Carcinoma and its Effects on Immune Cell Subgroup Infiltration.
    Yu D; Cheng J; Xue K; Zhao X; Wen L; Xu C
    Pathol Oncol Res; 2019 Oct; 25(4):1437-1443. PubMed ID: 30361911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.